MBBS OSCE · Dermatology / Facial Dermatology
OSCE — periorificial dermatitis: recognition, steroid withdrawal, and safe treatment ladder
An 8-minute OSCE station on recognising periorificial (perioral) dermatitis, linking topical steroid/fluorinated toothpaste triggers, planning steroid wean, and choosing topical/oral antibiotic therapy without restarting potent facial steroids.
8 min stationSource-verified ·
On this page
Study tools
Exam tags
NEET-PGINICETUSMLEPLABMRCP
Brief (to candidate)
A 28-year-old woman used a potent topical steroid cream for “eczema around the mouth” for 4 months. She now has crops of small erythematous papules and pustules around the mouth with a clear zone at the vermilion border; eyelids are mildly involved. Stopping the cream caused a rebound flare. You have 8 minutes to diagnose, counsel on steroid cessation, and plan therapy.
Candidate instructions
- Recognise periorificial dermatitis and the peri-vermilion spare zone.
- Link topical (and inhaled) corticosteroids and other triggers.
- Differentiate from acne, rosacea, seborrhoeic dermatitis.
- Plan steroid withdrawal plus first-line topical/systemic therapy.
- Counsel on expected rebound and follow-up.
Examiner checklist (mark each domain / 10)
| Domain | Key actions expected |
|---|---|
| Recognition | Discrete erythematous papules/pustules ± scale around mouth, nose, and/or eyes; characteristically spares a narrow zone at the vermilion border[1][3][6][9][15] |
| Triggers | Topical corticosteroids (most important), inhaled/nasal steroids, fluorinated toothpaste, cosmetics, moisturisers in some patients[1][4][5][7][15] |
| DDx | Acne, papulopustular rosacea (centro-facial), seborrhoeic dermatitis (greasy scale in seborrhoeic zones), allergic contact dermatitis[9][15] |
| Stop steroids | Cease facial potent TCS; expect temporary rebound flare — counsel and support rather than restart potent steroid cycle[5][6][7][15] |
| Treatment ladder | Zero-therapy / gentle care → topical metronidazole / ivermectin / calcineurin inhibitor / erythromycin as available → oral tetracycline-class (or erythromycin if tetracycline contraindicated) for more extensive disease; paediatric considerations for tetracyclines[2][3][5][6][8][9][15][27] |
| Safety | Avoid restarting clobetasol/potent face steroid; avoid heavy cosmetics and unnecessary skincare products; stop culprit toothpaste if implicated[15][16][22] |
| Communication | Explain diagnosis as steroid-related facial rash, timeline of improvement (weeks), when to return (eye symptoms, worsening)[1][15] |
Model key actions
- Diagnose periorificial dermatitis from papulopustular peri-oral distribution with vermilion spare zone and steroid history.[1][3][5][6][9]
- Stop facial corticosteroids and warn about rebound.[5][6][15]
- Start topical anti-inflammatory/antibiotic regimen ± oral tetracycline-class for moderate–severe disease.[2][5][6][9]
Common errors
- Restarting topical corticosteroids for the rebound flare — steroids may initially control the skin lesions, but disease often rebounds after discontinuing therapy; forewarn patients the condition will likely worsen until it improves with appropriate therapy.[6][15]
- Treating as acne with comedolytic isotretinoin pathway without recognising POD.[6][7][9][11][15]
- Missing inhaled steroid peri-oral/peri-oral nasal contribution.[7][15]
- Using tetracyclines in young children/pregnancy without alternative plan.[9][15][17][18]
- No counselling that improvement may take several weeks.[6][15]
References16ShowHide
- [1]Searle T, Ali FR, Al-Niaimi F. Perioral dermatitis: Diagnosis, proposed etiologies, and management J Cosmet Dermatol, 2021.PMID 33751778
- [2]Gray NA, Tod B, Rohwer A, et al. Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review J Eur Acad Dermatol Venereol, 2022.PMID 34779023
- [3]Acevedo-Fontanez LA, Sánchez-Feliciano A, Ershadi S, et al. Periorificial dermatitis: Pathophysiology, diagnosis, and management J Am Acad Dermatol, 2026.PMID 41197738
- [4]Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids J Am Acad Dermatol, 2006.PMID 16384751
- [5]Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options Am J Clin Dermatol, 2014.PMID 24623018
- [6]Mokos ZB, Kummer A, Mosler EL, et al. Perioral dermatitis: still a therapeutic challenge Acta Clin Croat, 2015.PMID 26415314
- [7]Kellen R, Silverberg NB. Pediatric periorificial dermatitis Cutis, 2017.PMID 29360899
- [8]Ollech A, Yousif R, Kruse L, et al. Topical calcineurin inhibitors for pediatric periorificial dermatitis J Am Acad Dermatol, 2020.PMID 32032693
- [9]Chiriac A, Chiriac AE, Madke B, et al. Periorificial dermatitis in infants and preschoolers - a narrative review Eur J Pediatr, 2025.PMID 39825187
- [11]Guarda D, Marquez P, Bascuñan G, Montane C. Recalcitrant Perioral Dermatitis Successfully Controlled With Low-Dose Isotretinoin: A Case Report Cureus, 2026.PMID 42037824
- [15]Tolaymat L, Syed HA, Hall MR. Perioral Dermatitis StatPearls [Internet], 2026.PMID 30247843
- [16]Peters P, Drummond C. Perioral dermatitis from high fluoride dentifrice: a case report and review of literature Aust Dent J, 2013.PMID 23981221
- [17]Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation? Expert Opin Drug Saf, 2016.PMID 26680308
- [18]Smith GN, Gemmill I, Moore KM. Management of tick bites and lyme disease during pregnancy J Obstet Gynaecol Can, 2012.PMID 23231847
- [22]Sethi P, Maheshwari K, Arora E, et al. Topical Steroid and Fairness Cream Abuse in Facial Dermatoses: A Cross-Sectional Study at a Tertiary Care Center in Western Uttar Pradesh Cureus, 2026.PMID 41959968
- [27]Correia MP, Fernandes S, de Vasconcelos P, et al. Childhood granulomatous periorificial dermatitis: Ivermectin as a novel therapeutic approach Dermatol Online J, 2026.PMID 42246357